During the past cycle, following consultation with our internal and external advisory boards, organizational governance structure and the leadership of NCRR, we have focused our efforts on two overarching themes - Translational Therapeutics and Bridging the Pediatric to Adult Divide, taking advantage of resources particular to our institutions. We have fostered interdisciplinary and translational research by a series of """"""""top down"""""""" and """"""""bottom up"""""""" funding initiatives. CTSA support and institutional investment aided by ARRA funding has increased dramatically the footprint of ITMAT more than 7 fold to -150,000 nsf comprising an expanded, integrated and re-purposed Clinical and Translational Research Center (CTRC) that succeeds the Penn and CHOP GCRCs, dry and wet bench laboratory space, a series of cores and a new home for ITMAT educational programs. ITMAT also supports seminars, workshops and an annual international meeting highlighting the opportunities that the CTSA affords on our campus to pursue clinical and translational research. Interdisciplinary research has increased dramatically on, between, and within the partner institutions during the past funding cycle and these trends have been most pronounced amongst members of ITMAT During the coming cycle we envisage the continued growth and development of our educational programs; the continued expansion - via recruitment and education - ofthe critical mass of investigators pursuant of clinical and translational research;enhancement and expansion of our core infrastructure and the development and expansion of programs focused on our two overarching themes. In particular we hope to impact patient care in the community by projecting our two strategic goals to alter the current paradigm of comparative effectiveness research by integrating expertise in basic, pediathc and adult pharmacology and to contribute to predictive strategies in the personalization of medicine.
PENN, CHOP, Monell, Wistar Institute, and the University ofthe Sciences of Philadelphia have benefited greatly from the first cycle of funding ofthe CTSA, which allowed the development of new centers, research programs, cores and a robust educational program which involve more than 800 investigators across campus and from partner institutions, as well as adding to consortial activities nationally.
Tolbert, Vanessa P; Coggins, Grace E; Maris, John M (2017) Genetic susceptibility to neuroblastoma. Curr Opin Genet Dev 42:81-90 |
Zanoni, Paolo; Khetarpal, Sumeet A; Larach, Daniel B et al. (2016) Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 351:1166-71 |
Parks, Elizabeth P; Kazak, Anne; Kumanyika, Shiriki et al. (2016) Perspectives on Stress, Parenting, and Children's Obesity-Related Behaviors in Black Families. Health Educ Behav 43:632-640 |
Strom, Brian L; Schinnar, Rita; Karlawish, Jason et al. (2015) Statin Therapy and Risk of Acute Memory Impairment. JAMA Intern Med 175:1399-405 |
Quatromoni, Jon G; Singhal, Sunil; Bhojnagarwala, Pratik et al. (2015) An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells. J Leukoc Biol 97:201-9 |
Dood, Robert L; Gracia, Clarisa R; Sammel, Mary D et al. (2014) Endometrial cancer after endometrial ablation vs medical management of abnormal uterine bleeding. J Minim Invasive Gynecol 21:744-52 |
Quatromoni, Jon G; Predina, Jarrod D; Bhojnagarwala, Pratik et al. (2014) Adenoviral-based immunotherapy provides local disease control in an orthotopic murine model of esophageal cancer. J Immunother 37:283-92 |
Quatromoni, Jon G; Suzuki, Eiji; Okusanya, Olugbenga et al. (2013) The timing of TGF-? inhibition affects the generation of antigen-specific CD8+ T cells. BMC Immunol 14:30 |
Guttmann, David M; Hart, Lori; Du, Kevin et al. (2013) Inhibition of Hsp27 radiosensitizes head-and-neck cancer by modulating deoxyribonucleic acid repair. Int J Radiat Oncol Biol Phys 87:168-75 |
Larach, Daniel B; Cuchel, Marina; Rader, Daniel J (2013) Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics. Clin Lipidol 8:635-648 |
Showing the most recent 10 out of 18 publications